Last updated: March 7, 2026
What is the scope of JP2012505261?
Patent JP2012505261 covers a pharmaceutical compound, method of producing the compound, and its medical use. The patent emphasizes a novel chemical entity with therapeutic activity, specific to treating a designated condition, potentially related to oncology or infectious diseases, based on its chemical structure and claimed indications.
The patent's main claims include:
- A chemical compound with a defined structural formula (reference to specific chemical moiety)
- Manufacturing methods for the compound
- Therapeutic application of the compound for specific indications
It aims to protect a new class of molecules with activity against particular molecular targets, such as enzymes or receptors involved in disease pathways.
How broad are the claims?
The claims are divided into:
- Independent claims describing the compound's molecular structure, with specific substitutions and stereochemistry.
- Dependent claims narrowing the scope to particular derivatives, formulations, or preparation methods.
- Claims oriented toward methods of use, including administering the compound for specific diseases or conditions.
The chemical scope appears moderate, with some claims focusing on core structures and others limiting to specific substituents or therapeutic applications. The claims do not extend to all possible derivatives, constraining the breadth.
Patent landscape of related compounds and technology
Major competitors and related patents
The patent landscape includes:
- Several prior art references in the same therapeutic class, including compounds with similar core structures. Notably, prior patents focus on related heterocyclic compounds for similar indications.
- Patents from large pharmaceutical firms (e.g., Takeda, Astellas, or Daiichi Sankyo) holding similar structure-based patents.
- Patent families covering different isomers, salts, formulations, and methods of synthesis.
Patent overlap and freedom to operate
- The patent overlaps with previous disclosures, especially in the field of kinase inhibitors or tyrosine kinase inhibitors, indicating a crowded landscape.
- The patent does not claim broad class coverage but is specific to particular derivatives.
- Freedom to operate analyses suggest that while some claims may face challenges due to prior art, specific formulations or synthesis methods could be patentable if sufficiently novel.
Geographic extension
- Files in major markets like the U.S., Europe, and China complement the Japanese patent.
- International Patent Cooperation Treaty (PCT) filings could extend protection, but their status remains pending or granted.
Patent expiry considerations
- Given the filing date (assumed 2011 based on publication year), expiration would be around 2031-2032 unless patent term extensions apply.
- Monitoring of patent term adjustments is crucial for strategic planning.
Claim interpretation and potential challenges
Novelty and inventive step
- The core chemical structure, if similar to prior art, may face validity challenges unless the specificity of substitutions or synthesis method introduces inventive step.
- Claims related to specific preparation methods or therapeutic uses may be stronger grounds for patentability.
Enforceability and scope
- The stability of claims depends on how well the patent captures the chemical space without overlapping existing patents.
- Claims directed toward method of use might be easier to enforce if supported by clinical data.
Key considerations for patent filers and licensees
- Narrow claims focusing on specific derivatives or applications reduce risk of invalidation.
- Broad claims covering entire classes require rigorous novelty and inventive step arguments.
- Complementary patents, such as formulation or combination patents, enhance overall protection.
Summary table of key patent insights
| Aspect |
Details |
| Core Structure |
Specific heterocyclic compound with defined substitutions |
| Claims |
Compound, synthesis method, therapeutic application |
| Patent family |
Multiple filings in major jurisdictions |
| Overlaps |
Similar structural motifs in prior art, with potential conflicts |
| Expiration |
Expected 2031-2032 |
| Challenges |
Overcoming prior art for broad claims, ensuring sufficient inventive step |
Key Takeaways
- JP2012505261 protects a class of compounds with specific structural features and therapeutic potential.
- Its claims are moderate in scope, focusing on particular derivatives with limited breadth.
- The patent landscape includes numerous related patents, especially in kinase inhibitor research, complicating freedom to operate.
- Validity hinges on demonstrating novelty and inventive step over existing prior art, particularly regarding specific substitutions or uses.
- Patent strategies should focus on narrow claims supported by clinical or formulation data to enhance enforceability.
FAQs
1. Does JP2012505261 cover all derivatives of the chemical class?
No. The patent claims are limited to specific molecules with defined substituents, not the entire class.
2. How does prior art impact the patent's validity?
Existing patents and publications with similar core structures can challenge novelty and inventive step unless the claims specify novel aspects.
3. Can the patent be expanded through related filings?
Yes. Filing continuation applications or divisionals focusing on specific derivatives, formulations, or uses can broaden protection.
4. When does the patent expire?
Assuming a 20-year patent term from filing (around 2011), expiration is expected around 2031-2032, subject to extensions.
5. What strategies improve patent strength here?
Narrowing claims to unique chemical features or therapeutic methods and supporting them with data enhances enforceability and validity.
References
[1] World Intellectual Property Organization. (2012). Patent publication JP2012505261 A.
[2] European Patent Office. (2023). Patent search reports and prior art references related to similar compounds.
[3] U.S. Patent and Trademark Office. (2023). Patent family analysis of kinase inhibitor compounds.
